Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
96.41 CHF | +1.01% |
|
-39.82% | -47.70% |
07-15 | Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing | MT |
07-12 | China approves CSPC Pharma's RSV vaccine for clinical trials | RE |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-47.70% | 46.56B | - | ||
+45.38% | 41.67B | A | ||
+0.69% | 41.16B | B | ||
+30.52% | 32.4B | B | ||
+22.30% | 28.18B | B- | ||
-6.35% | 28.1B | C | ||
+49.25% | 14.52B | B+ | ||
+49.18% | 13.74B | C+ | ||
+3.45% | 12.17B | B+ | ||
-3.85% | 11.14B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MRNA Stock
- 0QF Stock
- Ratings Moderna, Inc.